Un bon prix.  en ligne

Détails des produits

Created with Pixso. À la maison Created with Pixso. Produits Created with Pixso.
Médicaments contre le cancer du poumon
Created with Pixso. Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Nom De La Marque: Boehringer Ingelheim
Numéro De Modèle: Comprimés pelliculés à 18 mg
Quantité Minimale De Commande: 1 pièces
Prix: Please contact a specialist WhatsApp:55342706
Délai De Livraison: Négociable
Conditions De Paiement: Western Union, Moneygram, T / T
Informations détaillées
Lieu d'origine:
USA
Certification:
FDA NDA 218764
Spécification:
18mg*60 comprimés/boîte
Indications:
Fibrose pulmonaire idiopathique, fibrose pulmonaire progressive
Cible:
PDE4B
Nom du produit:
Nérandomilast
Recommandez:
Veuillez suivre les conseils du médecin.
Stockage:
Conserver entre 20°C et 25°C, en permettant des excursions de température ambiante entre 15°C et 30°
Température de stockage:
20°C à 25°C
Plage de température ambiante:
15°C à 30°C
Forme posologique:
Comprimé filmé
Force du comprimé:
18 mg ou moins
Taille du paquet:
60 comprimés/boîte
Enzyme cible:
PDE4B
Détails d'emballage:
Négociable
Capacité d'approvisionnement:
Négociable
Mettre en évidence:

Jascayd Nerandomilast 18mg Idiopathic Pulmonary Fibrosis

,

Generic Nerandomilast 18mg Progressive Pulmonary Fibrosis

,

Jascayd BI 1015550 IPF PPF Tablets

Description du produit
Jascayd Nerandomilast for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis Intervention
Product Overview

For professional medical use only under physician supervision

Manufacturer: Boehringer Ingelheim International GmbH

Generic Name: Nerandomilast

Brand Name: Jascayd

FDA Approval: NDA 218764

Indications

Jascayd is a highly selective PDE4B targeted inhibitor with anti-fibrotic and immunomodulatory effects. It is indicated for adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). May be used alone or in combination with standard anti-fibrotic agents such as pirfenidone or nintedanib to reduce lung capacity decline and delay disease progression.

Dosage and Administration

Standard Maintenance Dose: 18 mg orally twice daily, 12 hours apart. Swallow whole with room temperature water, before or after meals. Do not split, chew, or crush tablets.

  • Mild/Moderate Hepatic Impairment (Child-Pugh A/B): No dose adjustment required
  • Severe Hepatic Impairment & End-Stage Renal Disease: Insufficient safety data - not recommended

Missed Dose: Take immediately if remembered on the same day. If less than 4 hours until next dose, skip the missed dose. Do not take double dose.

Specifications

Film-coated oral tablets: 18 mg per tablet, 60 tablets per box

Contraindications
  • Patients with severe hypersensitivity to nerandomilast or any excipient component
  • Pregnant and breastfeeding women without professional risk-benefit assessment
Warnings and Precautions
  • Gastrointestinal Effects: Mild diarrhea, nausea, and stomach discomfort common during early treatment. Persistent severe GI reactions require medical evaluation and dose adjustment
  • Liver Function Monitoring: Regular liver function tests recommended during long-term use to monitor transient transaminase elevations
  • Drug Interactions: Metabolized by hepatic oxidation. Professional dose assessment required when used with strong CYP3A modulators
  • Fertility Considerations: Effective contraception recommended for patients of reproductive potential throughout treatment
Common Adverse Reactions (≥5% incidence)

Diarrhea, nausea, headache, fatigue, decreased appetite. Transient liver enzyme abnormalities frequently observed in laboratory tests.

Storage Requirements

Store at 20°C-25°C. Temporary exposure to 15°C-30°C acceptable. Protect from light. Keep in original packaging until use.